{"id":"npc-16-continuous-dosing-regimen-group","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to S1PR1, NPC-16 reduces the migration of immune cells to sites of inflammation, which may help to reduce the severity of autoimmune diseases. This mechanism of action is thought to be beneficial in the treatment of multiple sclerosis and other autoimmune conditions.","oneSentence":"NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune cell trafficking.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:29.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT02362711","phase":"PHASE3","title":"Efficacy and Safety, Long-Term Study of NPC-16 to Treat Dysmenorrhea","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2015-02","conditions":"Dysmenorrhea","enrollment":248}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg"],"phase":"phase_3","status":"active","brandName":"NPC-16 Continuous Dosing Regimen Group","genericName":"NPC-16 Continuous Dosing Regimen Group","companyName":"Nobelpharma","companyId":"nobelpharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"In a clinical trial for dysmenorrhea, the NPC-16 Continuous Dosing Regimen Group was one of the intervention groups studied. The trial, NCT02362711, was a Phase 3, placebo-controlled, randomized, double-blinded study of NPC-16 for the treatment of dysmenorrhea.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}